Zacks Investment Research·Jun 19, 2026
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant, Inc.(IMVT)Earnings, Financials & Key Ratios
IMVT•NASDAQ
$40.09
Price updated Jul 7, 2026
AboutImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.Show more
- Revenue$0
- EBITDA-$532M-21.6%
- Net Income-$506M-22.2%
- EPS (Diluted)-2.77-1.5%
- ROE-64.82%-3.8%
IMVT Price & Volume
Immunovant, Inc. (IMVT) stock price & volume — 10-year historical chart
Loading chart...
Escalating Clinical R&D Costs Drive Cash Burn
Investment Thesis • Updated 2026Q4
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
Key Thesis Takeaways
- Immunovant remains a pre-revenue biotechnology firm heavily reliant on equity-linked financing to sustain its FcRn-focused clinical pipeline.
- While the company maintains a robust liquidity position, the persistent escalation of R&D expenditures and widening operating losses necessitate careful monitoring of clinical trial milestones.
- Investors should remain cautious regarding the long-term dilution risks associated with funding a $1.7 billion cumulative deficit through continued equity issuance.
Verdict Logic
while the $902.1 million cash balance provides a sufficient runway for current clinical programs, the lack of commercial revenue and the $159.6 million quarterly operating loss suggest significant execution risk for long-term shareholders.
IMVT Growth Metrics
Immunovant, Inc. (IMVT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-22.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1.46%
Return on Capital
10 Years-56.07%
5 Years-55.11%
3 Years-63.17%
Last Year-68.29%
IMVT Recent Earnings
Immunovant, Inc. (IMVT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$0.73-23.3%
$0.59
Rev
—
—
Q1 2026
Feb 6, 2026Metric
Actual
Est
EPS
$0.61+15.3%
$0.72
Rev
—
$6M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.73-1.4%
$0.72
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.60+13.0%
$0.69
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.73vs $0.59-23.3% | — |
| Q1 2026 | Feb 6, 2026 | $0.61vs $0.72+15.3% | —vs $6M |
| Q4 2025 | Nov 10, 2025 | $0.73vs $0.72-1.4% | — |
| Q3 2025 | Aug 11, 2025 | $0.60vs $0.69+13.0% | — |
Based on last 12 quarters of dataView full earnings history →
Latest IMVT News
Recent stock market news and headlines for Immunovant, Inc. (IMVT)
Peers Comparison
Key metrics vs top competitors for Immunovant, Inc. (IMVT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $40.09 | $8.23B | -14.47 | — | — | -64.82% | — | |
| $5.38 | $1.32B | -20.69 | 22.09% | -13.58% | -38.11% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $42.13 | $4.88B | -13.21 | — | — | -71.31% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — |
Compare IMVT vs Peers
Immunovant, Inc. (IMVT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMVT SEC Filings & Documents
Immunovant, Inc. (IMVT) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
Feb 6, 2026·SEC
Material company update
Dec 12, 2025·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when IMVT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMVT Frequently Asked Questions
Immunovant, Inc. (IMVT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is IMVT profitable?
Immunovant, Inc. (IMVT) reported a net loss of $505.6M for fiscal year 2026.
Dividend & Returns
What is IMVT's return on equity?
Immunovant, Inc. (IMVT) has a return on equity (ROE) of -64.8%. Negative ROE indicates the company is unprofitable.
What is Immunovant, Inc.'s free cash flow?
Immunovant, Inc. (IMVT) had negative free cash flow of $407.3M in fiscal year 2026, likely due to heavy capital investments.